Tesamorelin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Acebutolol (has intrinsic sympathomimetic activity, ISA) Atenolol Betaxolol Bisoprolol Celiprolol (has intrinsic sympathomimetic activity) Metoprolol Nebivolol Esmolol Nebivolol and bisoprolol are the most β1 cardioselective beta blockers.
==== Mechanism of action ==== Cannabinoid inhibits the activity of both cannabinoid receptor 1 (CBR1) and cannabinoid receptor 2 (CBR2), with a stronger inhibitory effect observed in the former. Cannabidiol also interacts with non-cannabinoid receptors, including serotonin 1A receptors. Yet, the mechanism of cannabinoid in controlling seizures is not clearly established.
=== ASIC1a channel === Big dynorphin is a potent endogenous modulator of the acid-sensing ion channel 1a (ASIC1a) and current rescue following steady-state desensitization. In comparison, dynorphin A exhibits a approximately 1000-fold lower potency than big dynorphin at this target. Peptide potentiates ASIC1a current through a mechanism independent of both opioid and bradykinin receptor signaling. The potency correlates with big dynorphin's features, particularly its high net positive charge (9+) and abundance of arginine residues (6 total), with residues Arg6, Arg7. Big dynorphin rescues proton-gated currents and promotes acidosis-induced neuronal cell death in cultured cortical neurons, implicating it in pathological conditions involving cellular acidification and excitotoxicity.
In the Egyptian, Greek and Roman Empires, women usually fed only their own children. However, breastfeeding began to be seen as something too common to be done by royalty. Wet nurses were employed to breastfeed the children of the royal families. This extended over time, particularly in western Europe, where noble women often used wet nurses. Lower-class women breastfed their infants and used a wet nurse only if they were unable to feed their own infant. Attempts were made in 15th-century Europe to use cow or goat milk, but these attempts were unsuccessful. In the 18th century, flour or cereal mixed with broth was introduced as a substitute for breastfeeding, but this provided inadequate nutrition. The appearance of improved infant formulas in the mid-19th century and their increased use caused a decrease in breastfeeding rates, which accelerated after World War II. For some in the US, Canada, and the UK, breastfeeding was seen as uncultured. From the 1960s onwards, breastfeeding experienced a revival that continued into the 2000s, though negative attitudes towards the practice were still entrenched in some countries up to the 1990s.
Sources: en.wikipedia.org
=== Indices === Several stock market indices have been created which attempt to measure the megacap segment of the US stock market, and thus implicitly define versions of the megacap segment. Index funds have been created which track some of those indices. The Morningstar US Mega Cap Index "is designed to measure the performance of mega-cap US stocks, representing the top 70% of the investable market". Accordingly, as of June 2026, Morningstar Indexes defined its US megacap segment as companies with market caps greater than $94,234,256,812. As of August 31, 2026, the index contained 172 companies. The Vanguard Group issues an index ETF (NYSE Arca: MGC) that tracks this index. At initial creation circa February 2024, the MSCI USA Mega Cap Select Index consisted of companies in the MSCI USA Index with market caps of at least $200 billion. As of June 2026, the index's rules constrain it to contain 30 to 50 constituents. If possible while still complying with that minimum constituents requirement, new additions to the index are required to have a market cap of at least $220 billion. As of May 29, 2026, the index contained 50 constituents, with market caps ranging from $98.4 billion to $4.84 trillion. The Russell Top 200 Index is officially described as "[measuring] the performance of the mega cap segment of the US equity market". As of April 30, 2026, the Russell Top 200 contained 198 constituents, with market caps ranging from $62.1 billion to $4.85 trillion.
== Example: Insulin receptor downregulation == Elevated levels of the hormone insulin in the blood trigger downregulation of the associated receptors. When insulin binds to its receptors on the surface of a cell, the hormone receptor complex undergoes endocytosis and is subsequently attacked by intracellular lysosomal enzymes. The internalization of the insulin molecules provides a pathway for degradation of the hormone, as well as for regulation of the number of sites that are available for binding on the cell surface. At high plasma concentrations, the number of surface receptors for insulin is gradually reduced by the accelerated rate of receptor internalization and degradation brought about by increased hormonal binding. The rate of synthesis of new receptors within the endoplasmic reticulum and their insertion in the plasma membrane do not keep pace with their rate of destruction. Over time, this self-induced loss of target cell receptors for insulin reduces the target cell's sensitivity to the elevated hormone concentration. This process is illustrated by the insulin receptor sites on target cells, e.g. liver cells, in a person with type 2 diabetes. Due to the elevated levels of blood glucose in an individual, the β-cells (islets of Langerhans) in the pancreas must release more insulin than normal to meet the demand and return the blood to homeostatic levels.
A Pakistani newspaper, citing military sources, reported that seven TTP hideouts in Nangarhar, Paktika, and Khost provinces were destroyed and that more than 80 militants were killed; however, Taliban officials only reported airstrikes in the Nangarhar and Paktika provinces, adding that an airstrike in Bihsud District killed 18 civilians, including 11 children. Taliban officials condemned the airstrikes and warned of a calculated response at an appropriate time. Shayesteh Jan Ahadi, former head of the Paktia Provincial Council, stated that Pakistani airstrikes in several districts were very widespread and powerful. The United Nations Assistance Mission in Afghanistan (UNAMA) reported that Pakistan carried out airstrikes between 11:45 p.m. on 21 February and 12:15 a.m. on 22 February. UNAMA also reported that airstrikes in Paktika province damaged or destroyed infrastructure. On 23 February, UNAMA confirmed that over 13 civilians had been killed by the Pakistani airstrikes, with an additional seven injured. Pakistan described the operation as a retributive response to a series of suicide bombings inside Pakistan, including the 6 February bombing of a Shia mosque in Islamabad that killed 31 worshippers (claimed by ISIS–K), and attacks in Bajaur and Bannu districts in Khyber Pakhtunkhwa during the early days of Ramadan. Pakistan also claimed that the strikes were "intelligence-based, selective operations" against seven camps and hideouts belonging to the Tehreek-e-Taliban Pakistan (TTP), its affiliates, and the Islamic State – Khorasan Province (ISKP).
Sources: en.wikipedia.org
== Inventions == James Watt did not invent the steam engine, nor were his ideas on steam engine power inspired by a kettle lid pressured open by steam. Watt improved upon the already commercially successful Newcomen atmospheric engine (invented in 1712 by Thomas Newcomen) in the 1760s and 1770s, making certain improvements critical to its future usage; his new steam engine later gained huge fame as a result. Although the guillotine was named after the French physician Joseph-Ignace Guillotin, he neither invented nor was executed with this device. He died peacefully in his own bed in 1814. Rather, it was Guillotin's speech favoring beheadings over other forms of execution that led to the device being referred to as "La machine Guillotine" and later simply guillotine. Thomas Crapper did not invent the flush toilet. A forerunner of the modern toilet was invented by the Elizabethan courtier Sir John Harington in the 16th century, and in 1775 the Scottish mechanic Alexander Cumming developed and patented a design for a toilet with an S-trap and flushing mechanism. Crapper, however, did much to increase the popularity of the flush toilet and introduced several innovations in the late 19th century, holding nine patents, including one for the floating ballcock. Thomas Edison did not invent the light bulb.
Anterior vaginal wall prolapse Cystocele (bladder into vagina) Urethrocele (urethra into vagina) Cystourethrocele (both bladder and urethra) Posterior vaginal wall prolapse Enterocele (small intestine into vagina) Rectocele (rectum into vagina) Apical vaginal prolapse Uterine prolapse (uterus into vagina) Vaginal vault prolapse (roof of vagina) - after hysterectomy Pelvic floor dysfunction can result after treatment for gynecological cancers. Damage to the pelvic floor not only contributes to urinary incontinence but can also lead to pelvic organ prolapse. Pelvic organ prolapse occurs in women when pelvic organs (e.g. the vagina, bladder, rectum, or uterus) protrude into or outside of the vagina. The causes of pelvic organ prolapse are not unlike those that also contribute to urinary incontinence. These include inappropriate (asymmetrical, excessive, insufficient) muscle tone and asymmetries caused by trauma to the pelvis. Age, pregnancy, family history, and hormonal status all contribute to the development of pelvic organ prolapse. The vagina is suspended by attachments to the perineum, pelvic side wall and sacrum via attachments that include collagen, elastin, and smooth muscle. Surgery can be performed to repair pelvic floor muscles. The pelvic floor muscles can be strengthened with Kegel exercises. Disorders of the posterior pelvic floor include rectal prolapse, rectocele, perineal hernia, and several functional disorders, including anismus.
== References == Connaughton, R.M. (1992) [1988]. The War of the Rising Sun and Tumbling Bear: A Military History of the Russo-Japanese War 1904-5 (Reprint ed.). Routledge. ISBN 978-0415071437. Kajima, Morinosuke (1976). The Diplomacy of Japan, 1894-1922. Vol. 1: Sino-Japanese War and Triple Intervention. Tokyo: Kajima Institute of International Peace. Kowner, Rotem (2006). Historical Dictionary of the Russo-Japanese War. Scarecrow Press. ISBN 0-8108-4927-5.
=== End of Empire === By this time, the war was closing in on the embattled Emperor. A Union of Czech Deputies had already sworn an oath to a new Czechoslovak state independent of the Habsburg Empire on 13 April 1918; the prestige of the German Army had taken a severe blow at the Battle of Amiens; and, on 25 September 1918, Zita's brother-in-law King Ferdinand I of Bulgaria broke away from his allies in the Central Powers and sued for peace independently. Zita was with Charles when he received the telegram announcing Bulgaria's collapse. She remembered it "made it even more urgent to start peace talks with the Western Powers while there was still something to talk about." On 16 October, the Emperor issued a "People's Manifesto" proposing the empire be restructured on federal lines with each nationality gaining its own state. Instead, each nation broke away and the empire effectively dissolved. Leaving behind their children at Gödöllő, Charles and Zita travelled to the Schönbrunn Palace. By this time ministers had been appointed by the new state of "German-Austria", and by 11 November, together with the Emperor's spokesmen, they prepared a manifesto for Charles to sign. Zita, at first glance, mistook it for an abdication and made her famous statement:
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.